MyFinsight
Home
Blog
About
Proceeds (expenses) from
sale of common stock...
$2,870K
Proceeds from maturities
of short-term...
$12,532K
Proceeds from sale of
common stock pursuant...
$4K
Net cash provided by
financing activities
$1,249K
Net cash provided by
investing activities
$422K
Canceled cashflow
$1,625K
Canceled cashflow
$12,110K
Net increase in cash
and cash...
-$70K
Canceled cashflow
$1,671K
Stock option
compensation to employees and...
$637K
Accrued expenses
$159K
Accounts payable
$104K
Stock options issued
to consultants
$28K
Amortization of discount on
held-to-maturity securities
-$24K
Amortization of operating
lease right-of-use...
$10K
something is missing
-$1,625K
Disbursements to acquire
short-term investments
$12,110K
Net cash used in
operating activities
-$1,741K
Canceled cashflow
$962K
Interest income
$111K
Net loss
-$2,536K
Canceled cashflow
$111K
Prepaid expenses and
other current assets
$102K
Receivables
$56K
Operating lease liability
-$9K
Loss from operations
-$2,647K
Total operating
expenses
$2,647K
Back
Back
Cash Flow
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)
source: myfinsight.com